David Foehr Sells 569 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 569 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $11,260.51. Following the sale, the vice president directly owned 18,331 shares of the company’s stock, valued at $362,770.49. This represents a 3.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Foehr also recently made the following trade(s):

• On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The shares were sold at an average price of $19.98, for a total transaction of $15,604.38.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The shares were sold at an average price of $16.83, for a total value of $88,609.95.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $19.39 on Friday. The company has a quick ratio of 12.25, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The firm has a 50-day simple moving average of $21.17 and a 200-day simple moving average of $16.21. The stock has a market capitalization of $719.29 million, a price-to-earnings ratio of -13.19 and a beta of 1.03. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $25.37.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. On average, equities analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its position in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell in the 3rd quarter valued at about $33,000. CWM LLC increased its stake in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period.

Analyst Ratings Changes

CBLL has been the subject of a number of analyst reports. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. TD Cowen reiterated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group raised their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. decreased their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.